Drug Trial Radar · NCT06076291
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Sep 27, 2023
Primary completion
Mar 18, 2026
Study completion Mar 18, 2026
Sponsor
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy, or without available standard or curative therapy.
Conditions
- Advanced Solid Tumors
Interventions
SG1827Drug
PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Through study completion, an average of one year
- MTD/MAD/ RP2DTime frame: Through study completion, an average of one year
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of USTC
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Henan Cancer Hospital
Zhenzhou, Henan, China
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.